buy miss indic rx data
messag report result cabometyx sale miss
consensu line expect management cite rcc combin impact
tki monotherapi market would captur patient set
remain tki choic use stabil toward end
initi declin management also highlight trial success
pot tailwind uptak set potenti expand market
system therapi confid defend patent recent paragraph
iv notic maintain buy pt head pot catalyst phase trial
impact new combin regimen monotherapi tki util rcc
result cabometyx revenu miss report total revenu
street consensu surprisingli miss
cabometyx sale vs consensu line estim
see earn preview note sequenti qoq cabometyx declin
driven declin patient demand increas gross-to-net price
adjust off-set juli price increas inventori level remain similar
prior quarter low end histor rang declin patient demand driven
increas uptak rcc combin therapi keytruda inlyta
bavencio inlyta regimen fda approv impact
monotherapi tki market whole cabometyx histor saw use
share management view patient demand rcc potenti increas
brief paus rcc patient tki regimen progress
therapi repres major growth market cabometyx front-lin
use decreas front-lin combin took share remain prefer
monotherapi tki rcc continu grow rcc popul despit front-lin
dynam share management view tki combin taken
share rcc remain well pois treat patient upon progress
rcc given tki median progression-fre surviv month
believ sale growth may subsid quarter reach steadi state
recaptur rcc patient posit side management highlight front-lin
demand stabil head late initi decreas
management remain bullish opportun highlight recent success
trial potenti tailwind recal recent announc
avastin tecentriq improv mpf mo rel standard
care nexavar bayri studi highlight success
could repres tailwind promis new regimen expand potenti market
system therapi diseas set still see heavi use locoregion treatment
remain system therapi demonstr surviv
benefit all-com popul furthermor success recent miss
evalu opdivo vs nexavar may indic checkpoint
inhibitor may best use combin anti-angiogen agent set stage
nice tecentriq combin evalu phase
lawsuit file anda filer indic confid
legal team abil defend patent exclus view recal
recent receiv paragraph iv certif notic letter msn
pharmaceut challeng salt polymorph tablet formul method
use patent expir seek effect date pot anda approv
earlier among relief line expir salt
page analyst certif import disclosur
polymorph patent recent discuss patent attorney highlight
may sever potenti avenu defend salt polymorph patent
believ strong case may choos sue msn near term
address uncertainti around ip see review ip takeaway patent
pipelin option repres addit potenti upsid current
estim evalu cabometyx opdivo front-lin kidney
cancer vs sutent read interim data convict
trial potenti success given strong mechanist rational combin
inhibitor vs tki link though recent success competitor
tki combin rcc could repres key competit bar commerci uptak
beyond run phase trial post-iodin vegfr
inhibitor dtc cabo atezolizumab rog-sw liver cancer
cabo nivolumab /- ipilimumab also run signal-find
phase ib trial ad addit prostat cancer cohort mcrpc
patient prior enzalutamid abirateron without prior docetaxel
updat estim account result new opex guidanc maintain
buy rate pt end cash invest
modestli reduc near-term cabometyx revenu estim account near-term
potenti temporari commerci headwind rcc also modestli increas
near-term oper expens forecast given updat fy guidanc
 expens previous sg expens previous
 maintain buy pt
page analyst certif import disclosur
valuat risk
valu inc per share use dcf base valuat method
valuat includ commerci product cabometyx cometriq well probability-adjust cash
flow deriv compani pipelin royalti out-licens program use
discount rate termin growth rate appli termin year post-assum
gener entri cabozantinib
risk valuat inc includ regulatori commerci setback potenti
emerg new competitor lower product sale expect
page analyst certif import disclosur
licens contract revenu
total cost expens
interest incom net
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
